Literature DB >> 31091306

Cdkn2a (Arf) loss drives NF1-associated atypical neurofibroma and malignant transformation.

Steven D Rhodes1,2, Yongzheng He1, Abbi Smith1, Li Jiang1, Qingbo Lu1, Julie Mund1, Xiaohong Li1, Waylan Bessler1, Shaomin Qian1, William Dyer1, George E Sandusky3, Andrew E Horvai4, Amy E Armstrong1,2, D Wade Clapp1.   

Abstract

Plexiform neurofibroma (PN) tumors are a hallmark manifestation of neurofibromatosis type 1 (NF1) that arise in the Schwann cell (SC) lineage. NF1 is a common heritable cancer predisposition syndrome caused by germline mutations in the NF1 tumor suppressor, which encodes a GTPase-activating protein called neurofibromin that negatively regulates Ras proteins. Whereas most PN are clinically indolent, a subset progress to atypical neurofibromatous neoplasms of uncertain biologic potential (ANNUBP) and/or to malignant peripheral nerve sheath tumors (MPNSTs). In small clinical series, loss of 9p21.3, which includes the CDKN2A locus, has been associated with the genesis of ANNUBP. Here we show that the Cdkn2a alternate reading frame (Arf) serves as a gatekeeper tumor suppressor in mice that prevents PN progression by inducing senescence-mediated growth arrest in aberrantly proliferating Nf1-/- SC. Conditional ablation of Nf1 and Arf in the neural crest-derived SC lineage allows escape from senescence, resulting in tumors that accurately phenocopy human ANNUBP and progress to MPNST with high penetrance. This animal model will serve as a platform to study the clonal development of ANNUBP and MPNST and to identify new therapies to treat existing tumors and to prevent disease progression.
© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31091306      PMCID: PMC6687955          DOI: 10.1093/hmg/ddz095

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  28 in total

1.  Atypical neurofibromas in neurofibromatosis type 1 are premalignant tumors.

Authors:  Eline Beert; Hilde Brems; Bruno Daniëls; Ivo De Wever; Frank Van Calenbergh; Joseph Schoenaers; Maria Debiec-Rychter; Olivier Gevaert; Thomas De Raedt; Annick Van Den Bruel; Thomy de Ravel; Karen Cichowski; Lan Kluwe; Victor Mautner; Raf Sciot; Eric Legius
Journal:  Genes Chromosomes Cancer       Date:  2011-08-24       Impact factor: 5.006

2.  Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis.

Authors:  Moritz Bennecke; Lydia Kriegl; Monther Bajbouj; Kristin Retzlaff; Sylvie Robine; Andreas Jung; Melek C Arkan; Thomas Kirchner; Florian R Greten
Journal:  Cancer Cell       Date:  2010-08-09       Impact factor: 31.743

Review 3.  Histopathologic evaluation of atypical neurofibromatous tumors and their transformation into malignant peripheral nerve sheath tumor in patients with neurofibromatosis 1-a consensus overview.

Authors:  Markku M Miettinen; Cristina R Antonescu; Christopher D M Fletcher; Aerang Kim; Alexander J Lazar; Martha M Quezado; Karlyne M Reilly; Anat Stemmer-Rachamimov; Douglas R Stewart; David Viskochil; Brigitte Widemann; Arie Perry
Journal:  Hum Pathol       Date:  2017-05-24       Impact factor: 3.466

Review 4.  p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors.

Authors:  C Romagosa; S Simonetti; L López-Vicente; A Mazo; M E Lleonart; J Castellvi; S Ramon y Cajal
Journal:  Oncogene       Date:  2011-02-07       Impact factor: 9.867

5.  Malignant peripheral nerve sheath tumours in neurofibromatosis 1.

Authors:  D G R Evans; M E Baser; J McGaughran; S Sharif; E Howard; A Moran
Journal:  J Med Genet       Date:  2002-05       Impact factor: 6.318

6.  Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant mice.

Authors:  Tiffany Chang; Kimberly Krisman; Emily Harding Theobald; Jin Xu; Jon Akutagawa; Jennifer O Lauchle; Scott Kogan; Benjamin S Braun; Kevin Shannon
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

7.  MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.

Authors:  Walter J Jessen; Shyra J Miller; Edwin Jousma; Jianqiang Wu; Tilat A Rizvi; Meghan E Brundage; David Eaves; Brigitte Widemann; Mi-Ok Kim; Eva Dombi; Jessica Sabo; Atira Hardiman Dudley; Michiko Niwa-Kawakita; Grier P Page; Marco Giovannini; Bruce J Aronow; Timothy P Cripe; Nancy Ratner
Journal:  J Clin Invest       Date:  2012-12-10       Impact factor: 14.808

8.  Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.

Authors:  Feng-Chun Yang; David A Ingram; Shi Chen; Yuan Zhu; Jin Yuan; Xiaohong Li; Xianlin Yang; Scott Knowles; Whitney Horn; Yan Li; Shaobo Zhang; Yanzhu Yang; Saeed T Vakili; Menggang Yu; Dennis Burns; Kent Robertson; Gary Hutchins; Luis F Parada; D Wade Clapp
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

9.  Transient expression of the Arf tumor suppressor during male germ cell and eye development in Arf-Cre reporter mice.

Authors:  Adam Gromley; Michelle L Churchman; Frederique Zindy; Charles J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-04-01       Impact factor: 11.205

10.  PRC2 is recurrently inactivated through EED or SUZ12 loss in malignant peripheral nerve sheath tumors.

Authors:  William Lee; Sewit Teckie; Thomas Wiesner; Leili Ran; Carlos N Prieto Granada; Mingyan Lin; Sinan Zhu; Zhen Cao; Yupu Liang; Andrea Sboner; William D Tap; Jonathan A Fletcher; Kety H Huberman; Li-Xuan Qin; Agnes Viale; Samuel Singer; Deyou Zheng; Michael F Berger; Yu Chen; Cristina R Antonescu; Ping Chi
Journal:  Nat Genet       Date:  2014-09-21       Impact factor: 38.330

View more
  19 in total

1.  Genetic disruption of the small GTPase RAC1 prevents plexiform neurofibroma formation in mice with neurofibromatosis type 1

Authors:  Julie A Mund; SuJung Park; Abbi E Smith; Yongzheng He; Li Jiang; Eric Hawley; Michelle J Roberson; Dana K Mitchell; Mohannad Abu-Sultanah; Jin Yuan; Waylan K Bessler; George Sandusky; Shi Chen; Chi Zhang; Steven D Rhodes; D Wade Clapp
Journal:  J Biol Chem       Date:  2020-05-29       Impact factor: 5.157

2.  Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.

Authors:  Michael J Fisher; Chie-Schin Shih; Steven D Rhodes; Amy E Armstrong; Pamela L Wolters; Eva Dombi; Chi Zhang; Steven P Angus; Gary L Johnson; Roger J Packer; Jeffrey C Allen; Nicole J Ullrich; Stewart Goldman; David H Gutmann; Scott R Plotkin; Tena Rosser; Kent A Robertson; Brigitte C Widemann; Abbi E Smith; Waylan K Bessler; Yongzheng He; Su-Jung Park; Julie A Mund; Li Jiang; Khadijeh Bijangi-Vishehsaraei; Coretta Thomas Robinson; Gary R Cutter; Bruce R Korf; Jaishri O Blakeley; D Wade Clapp
Journal:  Nat Med       Date:  2021-01-13       Impact factor: 53.440

Review 3.  Heterozygous Tumor Suppressor Microenvironment in Cancer Development.

Authors:  Jean-Philippe Brosseau; Lu Q Le
Journal:  Trends Cancer       Date:  2019-08-15

4.  Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.

Authors:  Cleofe Romagosa; Eduard Serra; Bernat Gel; Miriam Magallón-Lorenz; Juana Fernández-Rodríguez; Ernest Terribas; Edgar Creus-Batchiller; Anna Estival; Diana Perez Sidelnikova; Héctor Salvador; Alberto Villanueva; Ignacio Blanco; Meritxell Carrió; Conxi Lázaro
Journal:  Hum Genet       Date:  2021-05-31       Impact factor: 4.132

Review 5.  State of the Art and Advances in Peripheral Nerve Surgery.

Authors:  Javier Robla-Costales; Carlos Rodríguez-Aceves; Fernando Martínez-Benia; Mariano Socolovsky
Journal:  Adv Tech Stand Neurosurg       Date:  2022

6.  Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival.

Authors:  Calixto-Hope G Lucas; Harish N Vasudevan; William C Chen; Stephen T Magill; Steve E Braunstein; Line Jacques; Sonika Dahiya; Fausto J Rodriguez; Andrew E Horvai; Arie Perry; Melike Pekmezci; David R Raleigh
Journal:  Neurooncol Adv       Date:  2020-10-01

7.  Stem-like cells drive NF1-associated MPNST functional heterogeneity and tumor progression.

Authors:  Daochun Sun; Xuanhua P Xie; Xiyuan Zhang; Zilai Wang; Sameer Farouk Sait; Swathi V Iyer; Yu-Jung Chen; Rebecca Brown; Dan R Laks; Mollie E Chipman; Jack F Shern; Luis F Parada
Journal:  Cell Stem Cell       Date:  2021-05-18       Impact factor: 25.269

8.  A molecular basis for neurofibroma-associated skeletal manifestations in NF1.

Authors:  Yun Ma; Andrea M Gross; Eva Dombi; Alexander Pemov; Kwangmin Choi; Katherine Chaney; Steven D Rhodes; Steven P Angus; Noah Sciaky; D Wade Clapp; Nancy Ratner; Brigitte C Widemann; Jonathan J Rios; Florent Elefteriou
Journal:  Genet Med       Date:  2020-06-30       Impact factor: 8.864

9.  Cdkn2a Loss in a Model of Neurofibroma Demonstrates Stepwise Tumor Progression to Atypical Neurofibroma and MPNST.

Authors:  Katherine E Chaney; Melissa R Perrino; Leah J Kershner; Ami V Patel; Jianqiang Wu; Kwangmin Choi; Tilat A Rizvi; Eva Dombi; Sara Szabo; David A Largaespada; Nancy Ratner
Journal:  Cancer Res       Date:  2020-08-19       Impact factor: 13.312

Review 10.  New Model Systems and the Development of Targeted Therapies for the Treatment of Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumors.

Authors:  Kyle B Williams; David A Largaespada
Journal:  Genes (Basel)       Date:  2020-04-28       Impact factor: 4.141

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.